Related Experiment Video

Updated: Mar 25, 2026

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

13.2K

Safety and tolerability of pneumococcal vaccines in children

Susanna Esposito1, Nicola Principi1

  • 1a Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation , Università degli Studi di Milano Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy.

Expert Opinion on Drug Safety
|March 1, 2016
PubMed

Insights

Pneumococcal vaccines are safe and recommended for children. Pneumococcal conjugate vaccines (PCVs) are preferred for their effectiveness, though ongoing surveillance for rare adverse events is crucial.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Pneumococcal vaccines have historically reduced disease burden from Streptococcus pneumoniae.
  • Established vaccines aim to mitigate medical, social, and economic impacts of pneumococcal diseases.

Purpose of the Study:

  • To review the safety and tolerability of current and historical pneumococcal vaccines in children.
  • To analyze the established doctrine on pneumococcal vaccine safety.

Main Methods:

  • Literature review of safety and tolerability data.
  • Analysis of post-marketing surveillance for adverse events.

Main Results:

  • Pneumococcal vaccines are generally safe and recommended for clinical use.
  • Pneumococcal conjugate vaccines (PCVs) are preferred in children due to superior immunogenicity and impact on nasopharyngeal carriage.
  • Severe adverse events following PCVs are rare, but vigilance is necessary.

Conclusions:

  • All marketed pneumococcal vaccines are safe and clinically recommended.
  • PCVs are the vaccines of choice for children, offering significant benefits.
  • Continued post-marketing surveillance is essential to monitor rare adverse events and ensure vaccine safety.
Abstract

Keywords:
10-valent pneumococcal conjugate vaccine13-valent pneumococcal conjugate vaccine23-valent pneumococcal polysaccharide vaccine7-valent pneumococcal conjugate vaccineadverse eventspneumococcal vaccines

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
726
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K